Igor Stukalin
Overview
Explore the profile of Igor Stukalin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nassar A, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, et al.
J Immunother Cancer
. 2025 Mar;
13(3).
PMID: 40032601
Background: Data on the safety profiles and clinical outcomes of patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs) are limited. Methods: This is an international...
2.
Tkachuk B, Stukalin I, Wang Y, Congly S
ACG Case Rep J
. 2025 Feb;
12(2):e01620.
PMID: 39911373
Hepatocellular carcinoma (HCC) is a leading cause of cancer morbidity and mortality worldwide. Common sites of metastases include the lungs, regional lymph nodes, bone, and adrenal glands. Although rare, distant...
3.
Stukalin I, Gupta M, Buhler K, Forbes N, Heitman S, Ma C
Curr Oncol
. 2024 Dec;
31(12):7765-7769.
PMID: 39727694
Background: Colorectal cancer is the third most common malignancy globally. Early-onset colorectal cancer (EOCRC) is becoming a growing healthcare focus globally, particularly in North America. We estimated trends in incidence,...
4.
Guo E, Gupta M, Rossong H, Boone L, Manoranjan B, Ahmed S, et al.
Neurooncol Pract
. 2024 Sep;
11(5):566-574.
PMID: 39279779
Background: The financial implications of central nervous system (CNS) cancers are substantial, not only for the healthcare service and payers, but also for the patients who bear the brunt of...
5.
Bultz B, Kelly B, Rosberger Z, Forbes C, Railton C, Tavener M, et al.
Support Care Cancer
. 2024 Aug;
32(9):584.
PMID: 39134893
Background: The aim of this study was to understand the experiences of young men with a diagnosis of testicular cancer (TC) using a narrative approach, with the intention of informing...
6.
Abbott A, Meyers D, Elmi-Assadzadeh G, Stukalin I, Marro A, Puloski S, et al.
Front Immunol
. 2024 Jul;
15:1379056.
PMID: 38957472
Background: Bone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to immune checkpoint inhibitors (ICIs). The purpose...
7.
Gupta M, Stukalin I, Meyers D, Heng D, Monzon J, Cheng T, et al.
Front Oncol
. 2024 Jun;
14:1385425.
PMID: 38884085
Background: The association between objective imaging response and first line immune checkpoint inhibitor (ICI) therapy regimes in advanced melanoma remains uncharacterized in routine practice. Methods: We conducted a multi-center retrospective...
8.
Cook S, Samuel V, Meyers D, Stukalin I, Litt I, Sangha R, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2352302.
PMID: 38236598
Importance: Immune-related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non-small cell lung cancer (NSCLC). However, studies have been small...
9.
Lim C, Ghosh S, Morrison H, Meyers D, Stukalin I, Kerba M, et al.
Curr Oncol
. 2023 Dec;
30(12):10396-10407.
PMID: 38132391
The PACIFIC trial led to a new standard of care for patients with locally advanced lung cancer, but real-world practice has demonstrated that immune checkpoint inhibitor (ICI) pneumonitis can lead...
10.
Woo T, Stukalin I, Ding P, Goutam S, Sander M, Ewanchuk B, et al.
Curr Oncol
. 2023 Oct;
30(10):8936-8947.
PMID: 37887546
: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. A retrospective,...